A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM

Overview

About this study

A total of 207 subjects will be randomized into the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

 

  • Patients must be between the ages of 18 and 78 years.
  • Patient must have a signed study informed consent prior to entering the study.
  • Histologically confirmed MM prior to enrollment and randomization.
  • At least 1 week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g., KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or last single agent chemotherapy (e.g., lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
  • Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator’s discretion.
  • The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Adequate organ function at screening as defined below:
    • Hematology:
      • White blood cell-count more than 2.5 x 10^9/L;
      • Absolute neutrophil count more than 1.5 x 10^9/L;
      • Platelet count more than 100 x 10^9/L.
    • Renal Function:
      • • Creatinine clearance (CrCl) value of ≥ 15 ml/min by MDRD equation
    • Hepatic function:
      • ALT and/or AST ≤ 2.5 x ULN;
      • Total Bilirubin ≤ 2.0 x ULN unless the subject has Gilbert disease.
    • Coagulation test:
      • INR or PT: ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants;
      • aPTT: ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
  • Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative urine/serum pregnancy test within 72 hours prior to G-CSF first administration.
  • Women of childbearing potential must agree to use 2 methods of effective contraception: One barrier method (e.g., diaphragm, or condom or sponge, each of which are to be combined with a spermicide) and one hormonal method, unless she uses a highly effective method. Highly effective methods of contraception include:
    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal;
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable;
    • Intrauterine device (IUD);
    • Intrauterine hormone-releasing system (IUS);
    • Bilateral tubal occlusion;
    • Vasectomised partner;
    • Sexual abstinence.
    • These methods must be used prior to study entry and for the duration of study participation through 30 days after the last dose of study treatment. Non-childbearing potential is defined as (by other than medical reasons):
      • ≥ 45 years of age and has not had menses for over 2 years;
      • Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a Follicle Stimulating Hormone (FSH) value in the postmenopausal range upon pretrial (screening) evaluation.
      • Post hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 weeks prior to screening. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure; otherwise the subject must be willing to use two adequate barrier methods throughout the study, starting with the Screening Visit, through 30 days after the last dose of study drug. Information must be captured appropriately within the site's source documents.
  • Male subjects must agree to use an adequate method of contraception starting with the first day of G-CSF treatment through 30 days after the last dose of study drug.

Exclusion Criteria:

 

  • Previous history of autologous or allogeneic-HCT.
  • Failed previous HSC collections or collection attempts.
  • Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
    • Dexamethasone: 7 days;
    • Thalidomide: 7 days;
    • Lenalidomide: 7 days;
    • Pamolidomide: 7 days;
    • Bortezomib: 7 days;
    • Carfilzomib: 7 days;
    • G-CSF: 14 days;
    • GM-CSF or Neulasta®: 21 days;
    • Erythropoietin or erythrocyte stimulating agents: 30 days;
    • Eltrombopag, romiplostim or platelet stimulating agents: 30 days;
    • Carmustine (BCNU): 42 days/6 weeks;
    • Daratumumab: 28 days;
    • Ixazomib: 7 days.
  • Received > 6 cycles lifetime exposure to thalidomide or lenalidomide.
  • Received > 8 cycles of alkylating agent combinations.
  • Received > 6 cycles of melphalan.
  • Received prior treatment with radioimmunotherapy (e.g. radionuclides, holmium).
  • Received prior treatment with venetoclax.
  • Plans to receive maintenance treatment within 60 days post-transplantation (e.g., lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.).
  • Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
  • Known active CNS metastases or carcinomatous meningitis.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
  • Has an active infection requiring systemic therapy or uncontrolled infection.
  • Has a known additional malignancy that is progressing or requires active treatment.
  • Has an underlying medical condition that would preclude study participation.
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  • O2 saturation < 92% (on room air).
  • Personal history or family history of Long QT Syndrome or Torsade de Pointes.
  • History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
  • Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Angina Pectoris Class > 2 or NYHA Heart Failure Class > 2.
  • ECG at Screening showing QTcF > 470 msec and/or PR > 280 msec.
  • Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception as detailed above, within the projected duration of the trial, starting with the Screening Visit through 30 days after the last dose of study drug.
  • Has a known history of HIV (HIV 1/2 antibodies)
  • Has known active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is detected).
  • Untreated or unsuccessfully treated Hepatitis B or C.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ivana Micallef, M.D.

Open for enrollment

Contact information:

Anton Mett CCRP

(507)538-9812

Mett.Anton@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Vivek Roy, M.D.

Open for enrollment

Contact information:

Ashley Newberry C.C.R.C., CCRP

(904)953-3817

Newberry.Ashley@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20425425

Mayo Clinic Footer